Fiche centre
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago — United States
Essais liés16clinical trials
VilleChicagolocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06053814
Essais cliniques associés
16| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Mycophenolate Mofetil | Lupus | Phase 2 | NCT05538208 | The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study | RECRUITING |
| Rhenium-186 Nanoliposome | Cancer | Phase 1 | NCT07061626 | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma | RECRUITING |
| Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy | Myopathies | À vérifier | NCT06503367 | Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy | RECRUITING |
| Deramiocel (CAP-1002) | Myopathies | Phase 3 | NCT05126758 | HOPE-3 — A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| NS-050/NCNP-03 | Myopathies | Phase 1/2 | NCT06053814 | NS-050/NCNP-03 in Boys With DMD (Meteor50) | ACTIVE_NOT_RECRUITING |
| adrenocorticotropin hormone | Épilepsie | Non applicable | NCT01367964 | PREVENT-WS — Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH) | TERMINATED |
| delandistrogene moxeparvovec | Myopathies | Phase 1 | NCT04626674 | ENDEAVOR — A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort | RECRUITING |
| SGT-003 | Myopathies | Phase 1/2 | NCT06138639 | A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | RECRUITING |
| ETX101 | Épilepsie | Phase 1/2 | NCT05419492 | ENDEAVOR — A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome | RECRUITING |
| RGX-202 | Myopathies | Phase 2/3 | NCT05693142 | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| EXCEL — A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition | Myopathies | À vérifier | NCT06581146 | EXCEL — A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition | RECRUITING |
| Anakinra (Kineret®) | Cancer | Phase 1 | NCT06703216 | PACER — Pre-emptive Anakinra for Cytokine Event Reduction | WITHDRAWN |
| Rimegepant | Migraine | Phase 3 | NCT06616194 | A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine | ACTIVE_NOT_RECRUITING |
| zorevunersen | Épilepsie | Phase 3 | NCT06872125 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | RECRUITING |
| SOM-L — Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome | Épilepsie | À vérifier | NCT05374824 | SOM-L — Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome | RECRUITING |
| Clemizole HCl | Épilepsie | Phase 3 | NCT04462770 | ARGUS — A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | RECRUITING |